VR Logo

Freeline Therapeutics Holdings plc (FRLN) download report


Healthcare | Biotechnology & Pharma Research

Freeline Therapeutics Holdings plc (FRLN) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases.

IPO Date: 07-Aug-2020

CEO, COO, Pres & Exec. Director: Mr. Michael J. Parini J.D.

Founder, Independent Clinical & Scientific Advisor and Director: Dr. Amit Chunilal Nathwani M.D., Ph.D.

Listing: NASDAQ: FRLN

Country: United Kingdom

Headquarters: Stevenage,

Website: https://www.freeline.life

Key Facts

Market cap: $57.61 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-132.18 Mln

Cash: $113.10 Mln

Total Debt: $59.63 Mln

Insider's Holding: 0.00%

Liquidity: Low

52 Week range: $0.65 - 15.40

Shares outstanding: 64,727,300

6 Years Aggregate:

  • CFO: $-298.36 Mln
  • EBITDA: $-335.79 Mln
  • Net Profit: $-323.91 Mln

Stock Performance

Time Period Freeline Therapeutics Holdings (FRLN) S&P BSE Sensex* S&P Small-Cap 600*
YTD-55.12-9.07-17.14
1 month29.53-3.48-4.85
3 months-20.66-7.65-12.74
1 Year-89.550.09-16.37
3 Years--10.207.97
5 Years--11.346.33
10 Years--12.0610.54
As on 27-Jun-2022 *As on 28-Jun-2022
Year Freeline Therapeutics Holdings (FRLN) S&P Small-Cap 600 S&P BSE Sensex
2021-89.1625.2721.99